{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-087464","form_type":"8-K","ticker":"REPL","cik":"0001737953","company_name":"Replimune Group, Inc.","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.843262+00:00","generated_at":"2026-05-17T08:19:44.980034+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Replimune schedules Type A meeting with FDA to discuss RP1 CRL; program viability at risk","bullets":["FDA Type A meeting scheduled to discuss CRL for RP1 BLA in advanced melanoma; briefing submitted with additional analysis.","CEO states without accelerated approval, RP1 program in advanced melanoma, including phase 3 confirmatory trial, will not be viable.","Stockholders voted against amending 2018 Omnibus Incentive Compensation Plan (26.97M for, 35.49M against).","All director nominees elected; PwC ratification and say-on-pay proposals approved by stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-087464","json":"https://secwatch.observer/filing/0001104659-25-087464.json","markdown":"https://secwatch.observer/filing/0001104659-25-087464.md","text":"https://secwatch.observer/filing/0001104659-25-087464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925087464/0001104659-25-087464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465925087464/tm2525185d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:19:44.980034+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}